Author: BusinessWire

Veeva eConsent makes it easier for patients to understand and provide electronic informed consent

Milestone accelerates industry’s move toward paperless, patient-centric trials
PLEASANTON, Calif.–(BUSINESS WIRE)–Veeva Systems (NYSE: VEEV) today ann…

Veeva eConsent makes it easier for patients to understand and provide electronic informed consent

Milestone accelerates industry’s move toward paperless, patient-centric trials
BARCELONA, Spain–(BUSINESS WIRE)–Veeva Systems (NYSE: VEEV) today annou…

Swiss Ewopharma to market Piclidenoson and Namodenoson in Central Eastern Europe (CEE)

$2.25 million upfront payment with an additional $40.45 million for regulatory & sales milestones and 17.5% royalties are included

PETACH TIKVA, Israel–(B…

Swiss Ewopharma to market Piclidenoson and Namodenoson in Central Eastern Europe (CEE)

$2.25 million upfront payment with an additional $40.45 million for regulatory & sales milestones and 17.5% royalties are included

PETACH TIKVA, Israel–(B…

— Brings 25 years of preclinical and clinical drug development experience to ReForm —
WOBURN, Mass.–(BUSINESS WIRE)–ReForm Biologics, a company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and …

— Brings 25 years of preclinical and clinical drug development experience to ReForm —
WOBURN, Mass.–(BUSINESS WIRE)–ReForm Biologics, a company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and …

Trial to enroll up to 30,000 volunteers worldwide

Fast Track designation granted by US FDA

Feasibility study initiated of a vaccine candidate to address emerging variants
QUEBEC CITY & LONDON–(BUSINESS WIRE)–Medicago, a biopharmaceutical company h…

Swiss Ewopharma to market Piclidenoson and Namodenoson in Central Eastern Europe (CEE)

$2.25 million upfront payment with an additional $40.45 million for regulatory & sales milestones and 17.5% royalties are included

PETACH TIKVA, Israel–(B…

MILAN, Italy–(BUSINESS WIRE)–$NWRN #schizophrenia–Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral ne…

Swiss Ewopharma to market Piclidenoson and Namodenoson in Central Eastern Europe (CEE)

$2.25 million upfront payment with an additional $40.45 million for regulatory & sales milestones and 17.5% royalties are included

PETACH TIKVA, Israel–(B…